ITRM ITERUM THERAPEUTICS PLC Product Launches 8-K Filing 2024 - Phase 3 Clinical Trial Results Iterum Therapeutics plc announced positive results from its Phase 3 clinical trial of Oral Sulopenem in uncomplicated urinary tract infections (uUTI), with statistically significant superiority over Augmentin.Get access to all SEC 8-K filings of the ITERUM THERAPEUTICS PLC